Anti-BCMA antibody produced in rabbit
SIGMA/PRS2397 - affinity isolated antibody, buffered aqueous solution
Synonym: Anti-Tumor necrosis factor receptor superfamily, member 17
Product Type: Chemical
Immunohistochemistry Anti-BCMA: Cat. No. PRS2397 Immunohistochemistry of BCMA in human spleen cells with BCMA antibody at 10 μg/mL.
Immunofluorescence Immunofluorescence of BCMA in Human Spleen tissue with BCMA antibody at 10 μg/mL.
Immunoblotting Anti-BCMA: Cat. No. PRS2397 Western blot analysis of BCMA in human spleen (A) tissue lysate, K562 (B), and U937 (C) cell lysates with BCMA antibody at 5 μg/mL.
| antibody form | affinity isolated antibody |
| antibody product type | primary antibodies |
| biological source | rabbit |
| clone | polyclonal |
| conjugate | unconjugated |
| form | buffered aqueous solution |
| mol wt | predicted mol wt 20 kDa |
| Quality Level | 100  |
| shipped in | dry ice |
| species reactivity | human |
| storage temp. | −20°C |
| target post-translational modification | unmodified |
| technique(s) | immunofluorescence: suitable |
| immunohistochemistry: suitable | |
| indirect ELISA: suitable | |
| western blot: suitable | |
| UniProt accession no. | Q02223  |
| Biochem/physiol Actions: | TNFRSF17 (tumor necrosis factor receptor superfamily member 17) is essential for the maintenance of the survival of long-lived plasma cells in bone marrow. Its expression in peripheral blood B-cells is induced by cytokines. It gets activated by a proliferation-inducing ligand (APRIL) or B-cell–activating factor (BAFF), and gets trimerized to activate MAPK (mitogen activated kinases) and anti-apoptotic proteins. It is an appropriate target for T-cells expressing chimeric antigen receptor (CAR), and is a promising candidate for adoptive T-cell therapy of multiple myeloma. This protein is directly cleaved and shed by γ-secretase enzyme, and this is linked with level of plasma cells in bone marrow. Thus, shedding of TNFRSF17 is a candidate biomarker for B-cell involvement in autoimmune diseases. This protein is thought to be a major contributor of spinal cord-injury induced autoimmunity. |
| Disclaimer: | Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals. |
| General description: | B-cell maturation antigen (BCMA), commonly known as TNFRSF17 (tumor necrosis factor receptor superfamily member 17), is an N-glycosylated membrane glycoprotein. It is predominantly expressed on the surface of plasma cells, and is also expressed on certain cancers such as, glioblastoma, chronic lymphocytic leukemia, Hodgkin′s lymphoma and multiple myeloma. |
| Immunogen: | a synthetic peptide mapping at the carboxy-terminus of human BCMA. |
| Other Notes: | The action of this antibody can be blocked using blocking peptide SBP2397 . |
| Physical form: | Solution in phosphate buffered saline containing 0.02% sodium azide |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 2 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Storage Temp. | −20°C |
| UNSPSC | 12352203 |